Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 59 min ago
PreprintCC BYbioRxiv

Multi-Lab Testing of Early Preclinical Discoveries Identifies Promising Treatments

  • P. Pellegrini
  • S. C. Rotter
  • M. Arroyo-Araujo
  • C. F. D. Carneiro
  • N. I. Drude
  • L. Martinez Gamboa
  • A. Banito
  • N. Bernhardt
  • A.-L. Boulesteix
  • F. Buttgereit
  • A. Dempfle
  • N. Duran-Hernandez
27 more authors
  • T. Gaber
  • M. Groettrup
  • B. Habelt
  • B. Haller
  • H. Hamza
  • S. Hettmer
  • A. Kliesow Remes
  • S. Kobold
  • M. Kochan
  • F. Konietschke
  • L. H. Lehmann
  • M. Löhning
  • A. Matzen
  • M. W. Meinhardt
  • H. Morrison
  • O. J. Müller
  • O. Planz
  • G. H. S. Richter
  • L. B. Riecken
  • S. K. Rosahl
  • K. Rubarth
  • K. Schmidt-Bleek
  • L. Schuler
  • A. Sharma
  • I. Skorodumov
  • R. Spanagel
  • I. Teichert-von Lüttichau
Read full textPDFDOICite

Abstract

A fundamental challenge in drug development is the frequent failure of early laboratory research to translate into clinical benefit. One promising solution is to confirm findings from exploratory single-laboratory studies across multiple laboratories before clinical testing. We investigated this approach following the conduct of preclinical multi-laboratory studies across different fields of medicine. For this, we evaluated effect sizes, experimental rigor, and a set of criteria to identify determinants of confirmation success. When tested under increased rigor, only a fraction of multi-laboratory studies confirmed the initial results. The underlying effect size reduction was associated with outcome-relevant experimental differences between exploratory and confirmatory stages. In summary, multi-laboratory studies proved highly informative and served as an effective filter for promising treatments.

Related

  1. Progress towards improving mouse models for preclinical testing of treatments for Alzheimer’s disease
    Michael Sasner, Claudia Rangel-Barajas, Adrian L. Oblak
    Mammalian GenomePeer-reviewedCC BY 4.0Full textNeurosciencePMC
  2. Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research
    Xavier Buin, Rosy Ghanem, Ines Pankonien +3
    PharmaceuticsPeer-reviewedCC BYGeneral biologyHAL
  3. Comprehensive preclinical reevaluation of PaBQU and DBQU regimens identifies lesional liability in hard-to-treat forms of tuberculosis
    N. D. Walter, L. M. Massoudi, A. A. Bauman +15
    bioRxivPreprintCC BYFull textMicrobiologybioRxiv
  4. Biomimetic scaffolds mimic human subretinal debris for preclinical testing of prosthetic vision
    M. B. Bhuckory, V. Mamchik, K. Ly +9
    bioRxivPreprintCC BYFull textSystems & synthetic biologybioRxiv
  5. Stimulation-stability and preclinical bench testing of a new auditory nerve interface.
    Taylor Stump, Stefan Strahl, Joseph Crew +9
    Bioelectronic medicinePeer-reviewedCC BY-NC-NDFull textNeuroscienceEurope PMC

Cite

BibTeXRIS
BibTeX
@misc{pellegrini2026multilab,
  title = {{Multi-Lab Testing of Early Preclinical Discoveries Identifies Promising Treatments}},
  author = {P. Pellegrini and S. C. Rotter and M. Arroyo-Araujo and C. F. D. Carneiro and N. I. Drude and L. Martinez Gamboa and A. Banito and N. Bernhardt and A.-L. Boulesteix and F. Buttgereit and A. Dempfle and N. Duran-Hernandez and T. Gaber and M. Groettrup and B. Habelt and B. Haller and H. Hamza and S. Hettmer and A. Kliesow Remes and S. Kobold and M. Kochan and F. Konietschke and L. H. Lehmann and M. Löhning and A. Matzen and M. W. Meinhardt and H. Morrison and O. J. Müller and O. Planz and G. H. S. Richter and L. B. Riecken and S. K. Rosahl and K. Rubarth and K. Schmidt-Bleek and L. Schuler and A. Sharma and I. Skorodumov and R. Spanagel and I. Teichert-von Lüttichau},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.21.753112},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.21.753112v1},
  note = {CC BY},
}
RIS
TY  - UNPB
TI  - Multi-Lab Testing of Early Preclinical Discoveries Identifies Promising Treatments
AU  - P. Pellegrini
AU  - S. C. Rotter
AU  - M. Arroyo-Araujo
AU  - C. F. D. Carneiro
AU  - N. I. Drude
AU  - L. Martinez Gamboa
AU  - A. Banito
AU  - N. Bernhardt
AU  - A.-L. Boulesteix
AU  - F. Buttgereit
AU  - A. Dempfle
AU  - N. Duran-Hernandez
AU  - T. Gaber
AU  - M. Groettrup
AU  - B. Habelt
AU  - B. Haller
AU  - H. Hamza
AU  - S. Hettmer
AU  - A. Kliesow Remes
AU  - S. Kobold
AU  - M. Kochan
AU  - F. Konietschke
AU  - L. H. Lehmann
AU  - M. Löhning
AU  - A. Matzen
AU  - M. W. Meinhardt
AU  - H. Morrison
AU  - O. J. Müller
AU  - O. Planz
AU  - G. H. S. Richter
AU  - L. B. Riecken
AU  - S. K. Rosahl
AU  - K. Rubarth
AU  - K. Schmidt-Bleek
AU  - L. Schuler
AU  - A. Sharma
AU  - I. Skorodumov
AU  - R. Spanagel
AU  - I. Teichert-von Lüttichau
PY  - 2026
DA  - 2026/09/21
PB  - bioRxiv
DO  - 10.64898/2026.09.21.753112
UR  - https://www.biorxiv.org/content/10.64898/2026.09.21.753112v1
AB  - A fundamental challenge in drug development is the frequent failure of early laboratory research to translate into clinical benefit. One promising solution is to confirm findings from exploratory single-laboratory studies across multiple laboratories before clinical testing. We investigated this approach following the conduct of preclinical multi-laboratory studies across different fields of medicine. For this, we evaluated effect sizes, experimental rigor, and a set of criteria to identify determinants of confirmation success. When tested under increased rigor, only a fraction of multi-laboratory studies confirmed the initial results. The underlying effect size reduction was associated with outcome-relevant experimental differences between exploratory and confirmatory stages. In summary, multi-laboratory studies proved highly informative and served as an effective filter for promising treatments.
ER  -